Fig. 6.

Anti‐TGF‐β antibody 1D11 induces durable increases in femoral strength (A,C), but has no effect on postyield displacement and toughness (B,D) in mice with osteogenesis imperfecta (OI) measured via three‐point bending test. Biomechanics femur n = 8, 5, 5, 8, 8, and 9 for groups 1–6, respectively. Mean ± SD and asterisk(s) denote statistically significant difference compared with OI 13C4, 10 mg/kg ip. ^a0.01 < p < 0.05. ^b0.001 < p < 0.01. ^c0.0001 < p < 0.001. ^d p < 0.0001. Dosing regimen: 3 × wk = three weekly doses; 1 × wk = 1 weekly dose; 1 × 2 wk = one dose every other week; 1 × 4 wk = one dose every 4 weeks; all doses 5 mg/kg ip. BV/TV = bone volume fraction; Tb.N = trabecular number; Tb.Sp = trabecular spacing; Tb.Th = trabecular thickness. [Correction added on 11 August 2021, after first online publication: Figure 6 has been replaced]